Chimeric HIV-1 Glycoproteins and Their Biological Applications
OwnerFrancisco Veas, Claudio Vita +6inventors
InventorsFrancisco Veas, Claudio Vita, Mireille C. Sauvage, Fabio Vita, Elena Vita, Loic Martin, Dorothy Bray, Kadija Benlhassan-Chahour
Life of this patent
Estimating the term…
Abstract
The invention relates to chimeric HIV-1 gp120 glycoproteins, wherein at least a part of gp120 variable region V1 and/or V2 is replaced by a CD4-derived sequence to obtain the exposition of CD4 induced epitopes or CD4i capable of inducing a specific humoral immune response. Application for the preparation of vaccinal and pharmaceutical composition.
Claims22
Chimeric HIV-1 gp120 glycoproteins, wherein at least a part of gp120 variable region V1 and/or V2 is replaced by a CD4-derived sequence to obtain the exposition of CD4 induced epitopes or CD4i capable of inducing a specific humoral immune response.
The chimeric HIV-1 gp120 glycoproteins of FIGS. 1B and 1C.
Dependencies are inferred from the claim text.